Key terms
About FORMYCON FLN 25/29
Sector
Health Technology
Industry
Pharmaceuticals: Major
Home page
ISIN
NO0013586024
FIGI
BBG01VT3FMZ9
Formycon AG engages in the manufacture of biosimilar drugs and formulations. Its product candidates include FYB201, FYB202, FYB203, and FYB205, which focuses in the opthalmology and immunology disease areas. The company was founded by Friedrich Wilhelm Steinweg and Nicolas Combé in 2007 and is headquartered in Munich, Germany.
Related bonds
Advanced bond data for paid plans
Unlock important bond data including coupon rates, redemption details, risk assessments, and much more.